2020 Year in Review - Biosimilars
2020 Year in Review - Biosimilars | January 25, 2021
The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.
2020 Year in Review - Biosimilars | January 25, 2021
Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials.
2020 Year in Review - Biosimilars | January 13, 2021
Simulation-modeling data demonstrate significant cost-savings by converting from reference pegfilgrastim with on-body injector to biosimilar pegfilgrastim-jmdb for prophylaxis of chemotherapy-induced neutropenia/febrile neutropenia in patients with diffuse large B-cell lymphoma (DLBCL).
2020 Year in Review - Biosimilars | January 13, 2021
The results of a phase 1 pharmacokinetic and safety equivalence study demonstrated equivalence between HD204 and both bevacizumab-EU and bevacizumab-US in healthy males.
2020 Year in Review - Biosimilars | January 13, 2021
Real-world national commercial administrative data showed that treatment adherence to infliximab biosimilar is high among patients who were infliximab-naïve, as well as those who had long exposure to infliximab.
2020 Year in Review - Biosimilars | January 13, 2021
The findings of an online, cross-sectional survey indicate oncologists were less likely to prescribe biosimilars if their practice could lose money and control of the drug, despite clinical safety and efficacy between the biosimilar and originator.
2020 Year in Review - Biosimilars | January 13, 2021
Real-world data indicate treatment adherence was highest among patients who had prior infliximab exposure but no prior infliximab biosimilar use.
2020 Year in Review - Biosimilars | January 13, 2021
Real-world data from the ONWARD study indicate that patients with inflammatory bowel syndrome (IBS) who initiate or switch to infliximab-dyyb achieve significant improvement of clinical outcomes and quality of life.
2020 Year in Review - Biosimilars | January 13, 2021
Data from a large, nationwide, observational cohort study demonstrate that switching from reference infliximab to biosimilar infliximab-abda in patients with inflammatory bowel disease was safe and efficacious compared with continuing reference infliximab.